.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,637,459

« Back to Dashboard

Details for Patent: 5,637,459

Title: Systematic evolution of ligands by exponential enrichment: chimeric selex
Abstract:Methods are disclosed for producing chimeric nucleic acid molecules with two or more functions. A chimeric library is generated in which individual chimeric molecules combine the functions or characteristics of two or more parent libraries, each parent library having been selected through the SELEX procedure for a specific function or feature. The chimeric molecules of this invention are useful in a variety of ways, including having improved affinities for a target molecule, enhancing assembly of multi-component molecules, and promoting reactions between two molecules.
Inventor(s): Burke; Donald (Boulder, CO), Tarasow; Ted (Boulder, CO), Eaton; Bruce E. (Boulder, CO), Gold; Larry (Boulder, CO)
Assignee: NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Filing Date:Aug 02, 1994
Application Number:08/284,063
Claims:1. A method of identifying chimeric nucleic acid ligands having high binding affinity for first and second target molecules from a chimeric nucleic acid ligand library, said method comprising:

a) preparing a chimeric nucleic acid ligand library generated according to a method comprising:

i) generating a first library of nucleic acid ligands selected through the SELEX procedure for binding to said first target molecule, said nucleic acid ligands having a 3' fixed sequence, and producing the double-stranded form of said first library of nucleic acid ligands;

ii) generating a second library of nucleic acid ligands selected through the SELEX procedure for binding to said second target molecule, said nucleic acid ligands having a 5' fixed sequence identical to the 3' fixed sequence of the nucleic acids of said first library, and producing the double-stranded form of said second library of nucleic acid ligands;

iii) mixing said first and second libraries under conditions which promote interlibrary annealing;

iv) forming chimeric nucleic acid ligands by enzymatically extending the recessed 3' ends while copying the 5' extensions of each annealed pair, to yield a double-stranded chimeric nucleic acid ligand library;

v) amplifying said double stranded nucleic acid ligand library chimeric;

b) contacting said amplified chimeric nucleic acid ligand library with said first and second target molecules, wherein chimeric nucleic acid ligands having an increased affinity to said first and second target molecules may be partitioned from the remainder of the chimeric nucleic acid ligand library;

c) partitioning said increased affinity chimeric nucleic acid ligands from the remainder of said chimeric nucleic acid ligand library; and

d) amplifying said increased affinity chimeric nucleic acid ligands to yield a mixture of chimeric nucleic acid ligands enriched in members which bind to said first and second target molecules, whereby chimeric nucleic acid ligands having high binding affinity to said first and second target molecules are identified.

2. A method of identifying chimeric nucleic acid ligands having high binding affinity for first and second target molecules from a chimeric nucleic acid ligand library, said method comprising:

a) preparing a chimeric nucleic acid ligand library generated according to a method comprising:

i) generating a first library of nucleic acid ligands selected through the SELEX procedure which bind to said first target molecules, said nucleic acid ligands having a 3' fixed sequence and a 5'-monophosphate;

ii) generating a second library of nucleic acid ligands selected through the SELEX procedure which bind to said second target molecule; and

iii) mixing said first and second libraries under conditions wherein the nucleic acid ligands of the first library are enzymatically or chemically joined to the nucleic acids of the second library to form chimeric nucleic acid ligands;

iv) amplifying said chimeric nucleic acid ligands, to yield said chimeric nucleic acid ligand library;

b) contacting said amplified chimeric nucleic acid ligand library with said first and second target molecules, wherein chimeric nucleic acid ligands having an increased affinity to said first and second target molecules may be partitioned from the remainder of the chimeric nucleic acid ligand library;

c) partitioning said increased affinity chimeric nucleic acid ligands from the remainder of said chimeric nucleic acid ligand library; and

d) amplifying said increased affinity chimeric nucleic acid ligands to yield a mixture of chimeric nucleic acid ligands enriched in members which bind to said first and second target molecules, whereby chimeric nucleic acid ligands having high binding affinity to said first and second target molecules are identified.

3. A method of identifying chimeric nucleic acid ligands having high binding affinity for a target molecule from a chimeric nucleic acid ligand library, said method comprising:

a) preparing a chimeric nucleic acid ligand library generated according to a method comprising:

i) generating a first library of nucleic acid ligands selected through the SELEX procedure for binding to said target molecule wherein each of said nucleic acid ligands is modified at the 3' end to facilitate linking of first and second members of said first library with each other; and

ii) chemically reacting said first and second members of said first library of nucleic acid ligands to form chimeric 3'-3'-linked nucleic acid ligands which comprise said chimeric nucleic acid library;

b) contacting said chimeric nucleic acid ligand library with said target molecule, wherein chimeric nucleic acid ligands having an increased affinity to said target molecule may be partitioned from the remainder of the chimeric nucleic acid ligand library;

c) partitioning said increased affinity chimeric nucleic acid ligands from the remainder of said chimeric nucleic acid ligand library; and

d) amplifying said first and second members of said increased affinity chimeric nucleic acid ligands, to yield a mixture of nucleic acid ligand members, enriched in nucleic acid ligand members which bind to said target molecule;

e) chemically reacting said mixture of amplified nucleic acid ligand members to form increased affinity chimeric 3'-3'-linked nucleic acid ligands, whereby chimeric nucleic acid molecules having high binding affinity to said target molecule are identified.

4. The method of claim 1, wherein said chimeric nucleic acid ligand library is generated according to a method further comprising between step v) and step b), the step:

transcribing said amplified double-stranded chimeric nucleic acid ligand library to yield a single-stranded RNA chimeric nucleic acid ligand library.

5. The method of claim 1, wherein said chimeric nucleic acid ligand library is generated according to a method further comprising between step v) and step b), the step:

vi) separating the strands of said amplified double-stranded chimeric nucleic acid ligand library to yield a single-stranded DNA chimeric nucleic acid ligand library.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc